Table 3 Subgroup analysis
Arthritis pain of patients with OA | Joint function of patients with OA | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Study characteristics | Datasets number | SMD (95% CI) | I2 (%) | P1 | P2 | Datasets number | SMD (95% CI) | I2 (%) | P1 | P2 |
Scale | ||||||||||
WOMAC | 5 | − 0.23 [− 0.45, − 0.02] | 67 | 0.03 | 5 | − 0.19 [− 0.36, − 0.02] | 49 | 0.03 | ||
Others | 4 | − 0.40 [− 0.67, − 0.13] | 19 | 0.003 | 0.33 | 3 | − 0.35 [− 0.65, − 0.05] | 0 | 0.02 | 0.34 |
Mean age | ||||||||||
< 65 years | 5 | − 0.40 [− 0.67, − 0.13] | 60 | 0.004 | 5 | − 0.29 [− 0.50, − 0.08] | 31 | 0.006 | ||
≥ 65 years | 4 | − 0.09 [− 0.19, 0.02] | 0 | 0.10 | 0.03 | 3 | − 0.12 [− 0.23, − 0.01] | 0 | 0.03 | 0.15 |
Dose of n− 3 PUFA | ||||||||||
< 1000 mg/d | 5 | − 0.11 [− 0.21, − 0.01] | 0 | 0.02 | 5 | − 0.14 [− 0.24, − 0.05] | 0 | 0.004 | ||
≥ 1000 mg/d | 4 | − 0.49 [− 0.86, − 0.11] | 69 | 0.01 | 0.09 | 3 | − 0.37 [− 0.80, 0.06] | 65 | 0.09 | 0.31 |
Dose of EPA | ||||||||||
< 500 mg/d | 4 | − 0.08 [− 0.19, 0.02] | 0 | 0.12 | 3 | − 0.11 [− 0.22, − 0.00] | 0 | 0.04 | ||
≥ 500 mg/d | 5 | − 0.39 [− 0.65, − 0.14] | 60 | 0.003 | 0.08 | 5 | − 0.31 [− 0.51, − 0.10] | 33 | 0.003 | 0.09 |
Dose of DHA (mg/d) | ||||||||||
< 500 mg/d | 5 | − 0.11 [− 0.21, − 0.01] | 0 | 0.02 | 5 | − 0.14 [− 0.24, − 0.05] | 0 | 0.004 | ||
≥ 500 mg/d | 4 | − 0.49 [− 0.86, − 0.11] | 69 | 0.01 | 0.09 | 3 | − 0.37 [− 0.80, 0.06] | 65 | 0.09 | 0.31 |
Follow− up duration | ||||||||||
< 6 months | 4 | − 0.39 [− 0.70, − 0.09] | 38 | 0.01 | 3 | − 0.33 [− 0.77, 0.11] | 60 | 0.15 | ||
≥ 6 months | 5 | − 0.23 [− 0.44, − 0.03] | 65 | 0.03 | 0.39 | 5 | − 0.14 [− 0.24, − 0.05] | 0 | 0.002 | 0.42 |